Latest news with #Dupixent
Yahoo
a day ago
- Business
- Yahoo
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Kymera Therapeutics, Inc. (NASDAQ:KYMR) stands against other top-performing stocks on Monday. Kymera Therapeutics saw its share prices surge by 45.51 percent on Monday to end at $43.13 apiece following the early-stage success of its drug candidate for the treatment of the moderate to severe form of eczema. In a statement, Kymera Therapeutics, Inc. (NASDAQ:KYMR) said that its primary objective to demonstrate that its drug candidate, KT-621, could achieve robust STAT6 degradation in blood and skin went 'well beyond our expectations.' A biopharmaceutical laboratory with scientists in lab coats working on medicines. The first phase of the trial enrolled 118 healthy volunteers who tested the safety and tolerability of KT-621. 'Building from the compelling preclinical data … is a powerful demonstration of what we believe is an impeccable translation into humans,' it said. If the drug succeeds all trials and secures regulatory approvals, it would rival Sanofi and Regeneron's blockbuster therapy, Dupixent. Following the trial results, Kymera Therapeutics, Inc. (NASDAQ:KYMR) earned a 'buy' recommendation and a higher price target of $51 from Bank of America, versus $44 previously. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Axios
2 days ago
- Business
- Axios
Sanofi buying Blueprint Medicines for up to $9.5 billion
Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts. Why it matters: This is Sanofi's third big buy in 2025, following Dren Bo and Vigil Neuroscience, as it tries to build up a portfolio that's become too reliant on its Dupixent anti-inflammatory drug. The situation that's been exacerbated by some recent clinical setbacks and the April sale of a control stake in its consumer health unit to Clayton Dubilier & Rice for €10 billion. By the numbers: Blueprint stockholders are slated to receive $129 per share at closing, representing a 23.3% premium over Friday's closing price. They'd also get contingent value rights that could include up to $6 in milestone payments.
Yahoo
2 days ago
- Business
- Yahoo
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company's expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median tmax of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day (PD): KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621. STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects' STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both. In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching >90% across all SAD doses starting at 6.25 mg. All SAD cohorts at 75 mg or greater doses achieved >95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects. In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg. Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose. In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg. Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg. Th2 Biomarkers: TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14. The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:SNY)/Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) Dupixent (dupilumab) healthy volunteer study. The safety profile of KT-621 was undifferentiated from that of the placebo. The company's KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively. Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Reuters
2 days ago
- Business
- Reuters
Sanofi finds M&A fix for its multiple itches
LONDON, June 2 (Reuters Breakingviews) - Sanofi ( opens new tab is one European giant that's still focused on the United States. The $123 billion French drugmaker will pay up to $9.5 billion, opens new tab for Blueprint Medicines (BPMC.O), opens new tab, a U.S. group whose key product fights a rare blood disorder which causes painful skin rashes. Aptly enough, it scratches a range of itches. Sanofi Chief Executive Paul Hudson has been in a tricky position. He needs to bolster his business to cope with a heavy reliance on eczema treatment Dupixent, which is expected to account for over a third of revenue this year, according to Visible Alpha data, but loses exclusivity early next decade. The strategy is to sell assets, like a stake in Sanofi's consumer drugs unit Opella, and invest more in new treatments. Yet the group's research record is patchy, as evidenced by recent, opens new tab underwhelming data for a much-fancied respiratory drug. The added risk is that Sanofi's pristine balance sheet, with debt equivalent to just a third of this year's EBITDA according to LSEG data, gets frittered away on expensive deals. Small wonder Sanofi is now worth just over 10 times forward earnings, a discount to European peers like Novartis (NOVN.S), opens new tab or AstraZeneca (AZN.L), opens new tab. Blueprint Medicines, however, may help assuage those M&A fears. Its key product, Ayvakit, is used to treat systemic mastocytosis, a condition that causes reactions like hives and even organ damage. Its niche status probably means it shouldn't be affected by the U.S. government's efforts to force drugmakers to cut prices by selling directly to consumers, JPMorgan analysts reckon. And, given Ayvakit is already approved and on the market, Sanofi is less exposed to the risk of failed trials, a key danger in biotech M&A. True, Blueprint does bring risks. Analysts expect Ayvakit sales to roughly quadruple by 2030 to over $2 billion, but as of now it makes operating losses. A rival treatment from Cogent Biosciences, with trial data expected this year, could lead to greater competition. All the same, there's a way to adequate returns, if shareholders are prepared to wait. In 2031, as per Visible Alpha forecasts, Blueprint could generate operating profit of $1.2 billion. That's obviously some way off, but it's also a near-11% post-tax return on his $9.2 billion outlay, after factoring in cash and assuming no cost savings. The pharma sector's cost of capital is less than 9%, according to NYU Stern School of Business estimates. If Hudson can find other viable targets, Sanofi's depressed shareholders may find more to cheer about. Follow @Unmack1, opens new tab on X
Business Times
2 days ago
- Business
- Business Times
Sanofi to buy US biopharma group Blueprint for up to US$9.5 billion
[PARIS] France's Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare blood disorder. The two companies said on Monday (Jun 2) that Sanofi would initially pay US$129.00 per share in cash, or around US$9.1 billion. Blueprint shares jumped 27 per cent to US$128.74 in premarket trade. Sanofi stock was down about 1 per cent. Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions. However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called 'smoker's lung' failed a late-stage trial. The Blueprint acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells – a type of white blood cell. It triggers a continuous allergic response. The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. The deal makes 'strategic and financial sense', said JPMorgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around US$2 billion by fiscal year 2030. 'We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time,' they added. It is the latest in a series of deals by Sanofi. Last month, it announced the US$470 million purchase of Vigil Neuroscience and in January 2024 it struck a US$2.2 billion deal for US biotech firm Inhibrx. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals. The company has said it plans to invest at least US$20 billion in the US through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing. Besides US$129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of US$2 and US$4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, is US$9.5 billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals. REUTERS
